Low-Dose Aspirin: Mechanism of Action

Aspirin is more than 120 years old, yet its mechanism was only explained in the 1970s, earning a Nobel Prize along the way. The way a small daily dose permanently disables platelets is one of the most elegant stories in pharmacology. Understanding it also explains why aspirin causes bleeding, why it interacts with ibuprofen and why dose matters less than many people assume.

From willow bark to Vane's discovery

Salicylate-containing plants such as willow bark have been used for pain and fever since antiquity. In 1897, chemists at Bayer produced acetylsalicylic acid, a less irritating derivative, and marketed it as Aspirin two years later.

For seven decades, nobody knew how it worked. The breakthrough came in 1971, when the British pharmacologist John Vane published evidence in Nature New Biology that aspirin and similar drugs inhibit the synthesis of prostaglandins. Vane shared the 1982 Nobel Prize in Physiology or Medicine for this work.

Prostaglandins and related molecules, collectively called prostanoids, are made from arachidonic acid by enzymes known as cyclooxygenases, or COX. They regulate inflammation, pain, fever, stomach protection, kidney blood flow and blood clotting.

A few years later, Roth and Majerus showed that aspirin acetylates a protein in platelets, transferring its acetyl group permanently. This detail is the key to aspirin's unusual antiplatelet properties.

Irreversible blocking of COX-1

There are two main cyclooxygenase enzymes. COX-1 is present in most tissues and handles routine "housekeeping" functions, including platelet activation and protection of the stomach lining. COX-2 is largely induced during inflammation, although it is also constitutively present in some tissues such as the kidney and blood vessel walls.

Aspirin attaches an acetyl group to a specific serine residue (serine 529 in human COX-1) inside the enzyme's channel. This physically blocks arachidonic acid from reaching the active site. Unlike ibuprofen or naproxen, which bind reversibly and wash out, aspirin's block is permanent for the life of that enzyme molecule.

Aspirin is roughly 150 to 200 times more potent against COX-1 than COX-2 in laboratory assays. At low doses, therefore, it acts mainly on COX-1, and its anti-inflammatory effect, which relies on COX-2 inhibition at higher doses, is minimal.

Acetylated COX-2 behaves differently: rather than being completely shut down, it switches to producing alternative lipid mediators, including aspirin-triggered lipoxins described by Clària and Serhan. Their clinical importance is still being explored.

Why platelets are uniquely affected

Platelets are small cell fragments without a nucleus. That means they cannot make new proteins. Once aspirin has acetylated a platelet's COX-1, that platelet is unable to produce thromboxane A2 for the rest of its life, roughly 7 to 10 days.

Thromboxane A2 is a powerful signal that makes platelets stick together and causes blood vessels to narrow. Blocking it reduces the tendency to form clots in arteries, especially on ruptured atherosclerotic plaques, which is the mechanism behind most heart attacks and many strokes.

Cells lining the blood vessels, by contrast, have nuclei and can synthesise new COX within hours. They produce prostacyclin, which opposes platelet clumping. With low-dose aspirin, prostacyclin production recovers between doses while platelet thromboxane remains suppressed. This selectivity is the pharmacological rationale for using low rather than high doses.

There is also a "presystemic" effect: much of an oral dose acts on platelets passing through the gut and portal circulation before the drug is broken down in the liver, which further limits exposure of the rest of the body.

Dose, timing and the ibuprofen interaction

Because the effect is cumulative and irreversible, small daily doses are enough. As Patrono and colleagues have explained, about 30 mg daily can almost completely suppress platelet thromboxane within a week, and the 75 mg dose standard in the UK achieves this reliably. Higher doses add stomach risk without clear antiplatelet benefit.

A study by Catella-Lawson and colleagues showed that taking ibuprofen before aspirin can block aspirin's access to COX-1, preventing its lasting antiplatelet effect. Regular ibuprofen use can therefore undermine aspirin's protection in people who need it. Occasional use is less of a concern, but anyone taking aspirin for heart protection should ask a pharmacist about painkiller choice.

Body size may matter too. An analysis by Rothwell and colleagues in 2018 suggested that 75–100 mg doses were less effective in people weighing over about 70 kg. This remains an area of active research and does not justify self-adjusting doses.

The flip side: effects on the stomach and kidneys

The same COX-1 inhibition that protects against clots also removes prostaglandins that maintain the stomach's mucus barrier and blood flow. This is why aspirin can cause indigestion, ulcers and gastrointestinal bleeding, even at 75 mg.

• Reduced protective prostaglandins in the stomach lining.
• Prolonged bleeding time because platelets cannot clump effectively.
• In susceptible people, worsening of asthma through shifts in leukotriene production.
• At high doses, effects on kidney blood flow and uric acid handling.

Doctors may prescribe a proton pump inhibitor alongside aspirin for patients at high risk of gastrointestinal bleeding. Enteric coating does not remove the systemic effect on the gut.

For athletes, these mechanisms are worth understanding: aspirin is not a training aid, and combining it with other anti-inflammatories, dehydration and intense exercise may add stress to the stomach and kidneys.

Conclusions of the editorial team

Low-dose aspirin works by permanently acetylating COX-1 in platelets, switching off thromboxane production for the life of each platelet.

This explains why tiny doses are effective, why the effect lasts days after the last tablet and why bleeding is the main risk.

Understanding the mechanism also clarifies practical issues such as the interaction with ibuprofen and the limited value of enteric coating.

To continue reading, see our articles on common myths about low-dose aspirin, on how anti-inflammatory painkillers affect athletes, and on stomach protection when taking long-term medicines.

References

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231(25):232–235.
2. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest. 1975;56(3):624–632.
3. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353(22):2373–2383.
4. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345(25):1809–1817.
5. Rothwell PM, Cook NR, Gaziano JM, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet. 2018;392(10145):387–399.
6. Clària J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci U S A. 1995;92(21):9475–9479.
7. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–1860.